Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDE892 as Monotherapy and Combination Therapy in MTAP-Deleted Advanced Solid Tumors
NCT07277413Phase 1Recruiting
- Sponsor
- IDEAYA Biosciences
- Start
- Mar 2026
- Primary completion
- Apr 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of IDE892 in solid tumor, non-small cell lung cancer (NSCLC), gastroesophageal junction cancer and 4 more (4 arms), sponsored by IDEAYA Biosciences. Primary endpoints: Dose-limiting Toxicities at 21 days, Adverse Events and Serious Adverse Events and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
IDE892
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)gastroesophageal junction cancerurothelial carcinoma (UC)mesothelioma
Beyond the preview
Go deeper on NCT07277413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07277413.